Defending against SARS-CoV-2: The T cell perspective DOI Creative Commons
Patricia Almendro-Vázquez, Rocío Laguna‐Goya,

Estela Paz‐Artal

и другие.

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Янв. 27, 2023

SARS-CoV-2-specific T cell response has been proven essential for viral clearance, COVID-19 outcome and long-term memory. Impaired early cell-driven immunity leads to a severe form of the disease associated with lymphopenia, hyperinflammation imbalanced humoral response. Analyses acute SARS-CoV-2 infection have revealed that mild course is characterized by an induction specific cells within first 7 days symptoms, coordinately followed antibody production effective control infection. In contrast, patients who do not develop cellular initiate immune subsequent high levels antibodies, symptoms. Yet, delayed persistent bystander CD8+ activation also reported in hospitalized could be driver lung pathology. Literature supports maintenance appears more stable than titters. Up date, virus-specific memory detected 22 months post-symptom onset, predominant IL-2 compared IFN-γ. Furthermore, responses are conserved against emerging variants concern (VoCs) while these mostly able evade responses. This partly explained HLA polymorphism whereby epitope repertoire recognized differ among individuals, greatly decreasing likelihood escape. Current COVID-19-vaccination shown elicit Th1-driven spike-specific response, as does natural infection, which provides substantial protection death. addition, mucosal vaccination induce strong adaptive both locally systemically protect VoCs animal models. The optimization vaccine formulations including variety regions, innovative adjuvants or diverse administration routes result desirable enhanced memory, help prevent breakthrough infections. summary, increasing evidence highlights relevance monitoring only levels, correlate after and/or vaccination. Moreover, it may better identify target populations benefit most from booster doses personalize strategies.

Язык: Английский

SARS-CoV-2 viral load and shedding kinetics DOI Open Access
Olha Puhach, Benjamin Meyer, Isabella Eckerle

и другие.

Nature Reviews Microbiology, Год журнала: 2022, Номер unknown

Опубликована: Дек. 2, 2022

Язык: Английский

Процитировано

332
A multinational Delphi consensus to end the COVID-19 public health threat DOI Creative Commons
Jeffrey V. Lazarus, Diana Romero, Christopher J. Kopka

и другие.

Nature, Год журнала: 2022, Номер 611(7935), С. 332 - 345

Опубликована: Ноя. 3, 2022

Abstract Despite notable scientific and medical advances, broader political, socioeconomic behavioural factors continue to undercut the response COVID-19 pandemic 1,2 . Here we convened, as part of this Delphi study, a diverse, multidisciplinary panel 386 academic, health, non-governmental organization, government other experts in from 112 countries territories recommend specific actions end persistent global threat public health. The developed set 41 consensus statements 57 recommendations governments, health systems, industry key stakeholders across six domains: communication; systems; vaccination; prevention; treatment care; inequities. In wake nearly three years fragmented national responses, it is instructive note that highest-ranked call for adoption whole-of-society whole-of-government approaches 1 , while maintaining proven prevention measures using vaccines-plus approach 2 employs range financial support complement vaccination. Other with at least 99% combined agreement advise governments improve communication, rebuild trust engage communities 3 management responses. findings which have been further endorsed by 184 organizations globally, include points unanimous agreement, well >5% disagreement, provide social policy address inadequacies help bring an end.

Язык: Английский

Процитировано

177
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial DOI Open Access
Jingxin Li, Shipo Wu,

Xiling Guo

и другие.

The Lancet Respiratory Medicine, Год журнала: 2022, Номер 10(8), С. 739 - 748

Опубликована: Май 20, 2022

Язык: Английский

Процитировано

124
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1 DOI Creative Commons
Qian Wang, Yicheng Guo, Anthony Bowen

и другие.

Cell Host & Microbe, Год журнала: 2024, Номер 32(3), С. 315 - 321.e3

Опубликована: Фев. 19, 2024

COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report administration an monovalent mRNA vaccine booster (XBB.1.5 MV) previously uninfected individuals boosted serum virus-neutralizing antibodies significantly not only (27.0-fold increase) EG.5.1 (27.6-fold also key emerging such as HV.1, HK.3, JD.1.1, JN.1 (13.3- 27.4-fold increase). Individuals infected by Omicron subvariant had highest overall neutralizing titers (ID

Язык: Английский

Процитировано

116
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models DOI Creative Commons
Renee L. Hajnik, Jessica A. Plante, Yuejin Liang

и другие.

Science Translational Medicine, Год журнала: 2022, Номер 14(662)

Опубликована: Сен. 14, 2022

Emergence of SARS-CoV-2 variants concern (VOCs), including the highly transmissible Omicron and Delta strains, has posed constant challenges to current COVID-19 vaccines that principally target viral spike protein (S). Here, we report a nucleoside-modified messenger RNA (mRNA) vaccine expresses more conserved nucleoprotein (mRNA-N) show mRNA-N vaccination alone can induce modest control SARS-CoV-2. Critically, combining with clinically proven S-expressing mRNA (mRNA-S+N) induced robust protection against both variants. In hamster models VOC challenge, demonstrated that, compared mRNA-S alone, combination mRNA-S+N not only in lungs but also provided enhanced upper respiratory tract. vivo CD8

Язык: Английский

Процитировано

99
SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic DOI Creative Commons
Antonio Bertoletti, Nina Le Bert, Anthony T. Tan

и другие.

Immunity, Год журнала: 2022, Номер 55(10), С. 1764 - 1778

Опубликована: Авг. 18, 2022

Язык: Английский

Процитировано

98
Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination DOI
Alexandra Suberi, Molly K. Grun, Tianyang Mao

и другие.

Science Translational Medicine, Год журнала: 2023, Номер 15(709)

Опубликована: Авг. 16, 2023

An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally invasive and lung-targeted delivery a host of pulmonary diseases. Development mRNA has been limited by poor transfection efficiency risk vehicle-induced pathology. Here, we report an polymer-based vehicle therapeutic mRNAs to the lung. We optimized biodegradable poly(amine- co -ester) (PACE) polyplexes using end-group modifications polyethylene glycol. These achieved high throughout lung, particularly in epithelial antigen-presenting cells. applied this technology develop mucosal vaccine severe acute respiratory syndrome coronavirus 2 found that intranasal vaccination with spike protein–encoding induced potent cellular humoral adaptive immunity protected susceptible mice from lethal viral challenge. Together, these results demonstrate translational potential PACE lungs.

Язык: Английский

Процитировано

87
Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report DOI Creative Commons
Jane M. Knisely, Lucas E. Buyon, Rebecca Mandt

и другие.

npj Vaccines, Год журнала: 2023, Номер 8(1)

Опубликована: Апрель 12, 2023

On November 7th and 8th, 2022, The National Institute of Allergy Infectious Diseases (NIAID), part the Institutes Health (NIH), Coalition for Epidemic Preparedness Innovation (CEPI), Bill & Melinda Gates Foundation (BMGF), Biomedical Advanced Research Development Authority (BARDA), Wellcome Trust hosted a virtual workshop entitled "Mucosal Vaccines SARS-CoV-2: Scientific Gaps Opportunities." During workshop, researchers vaccine developers from around world discussed potential mucosal vaccines to block SARS-CoV-2 transmission reviewed status research. Here, we summarize key challenges opportunities in basic, translational, clinical research that were highlighted during meeting. We also provide recommendations advance field accelerate development SARS-CoV-2.

Язык: Английский

Процитировано

74
Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization DOI
Tong Ye, Zhouguang Jiao, Xin Li

и другие.

Nature, Год журнала: 2023, Номер 624(7992), С. 630 - 638

Опубликована: Дек. 13, 2023

Язык: Английский

Процитировано

69
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters DOI Creative Commons
Geraldine Nouailles, Julia M. Adler, Peter Pennitz

и другие.

Nature Microbiology, Год журнала: 2023, Номер 8(5), С. 860 - 874

Опубликована: Апрель 3, 2023

Abstract Vaccines play a critical role in combating the COVID-19 pandemic. Future control of pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and ability to reduce virus transmission. Here we compare immune responses preclinical mRNA vaccine BNT162b2, adenovirus-vectored spike Ad2-spike live-attenuated candidate sCPD9 Syrian hamsters, using both homogeneous heterologous vaccination regimens. Comparative was assessed by employing readouts from titrations single-cell RNA sequencing. Our results show that elicited most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation pre-plasmablasts, strong systemic mucosal humoral responses, recall memory T cells lung after challenge SARS-CoV-2. Overall, our demonstrate offer advantages over currently available vaccines.

Язык: Английский

Процитировано

66